Press Releases

Year

November 15, 2021

Osmotica Pharmaceuticals plc Reports Third Quarter 2021 Results and Provides Business Update

Third quarter Upneeq® product sales of $2.2 million, representing 47% growth over second quarter sales Expansion of Upneeq launch continues with introduction of Direct Dispense program in eyecare and formation of Aesthetics business unit Sale of legacy business and capital raises streamlined

November 11, 2021

Osmotica Pharmaceuticals plc to Provide Third Quarter 2021 Business and Financial Update on November 15, 2021

BRIDGEWATER, N.J., Nov. 11, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that the Company will release its 2021 third quarter financial results on Monday, November 15, 2021, after the close of

October 13, 2021

Osmotica Pharmaceuticals plc Announces Closing of $35 Million Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 13, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that on October 12, 2021, it closed its previously announced underwritten public offering of 14,000,000 ordinary shares

October 7, 2021

Osmotica Pharmaceuticals plc Announces Debt Financing from Athyrium Capital Management of up to $100 Million

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has entered into a note purchase agreement for up to $100 million of senior secured notes with funds managed by

October 7, 2021

Osmotica Pharmaceuticals Announces Pricing of $35 Million Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced the pricing of its previously announced underwritten public offering of 14,000,000 ordinary shares of the Company and

October 6, 2021

Osmotica Pharmaceuticals plc Announces Proposed Underwritten Public Offering

BRIDGEWATER, N.J., Oct. 06, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, today announced that it has commenced an underwritten public offering of its ordinary shares and warrants to purchase its ordinary

September 22, 2021

Osmotica Pharmaceuticals plc to Present at Cantor Virtual Global Healthcare Conference 2021

BRIDGEWATER, N.J., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a specialty pharmaceutical company, announced today that Brian Markison, Chief Executive Officer, James “JD” Schaub, Chief Operating Officer, and Andrew Einhorn, Chief

September 2, 2021

Osmotica Pharmaceuticals plc to Present at H.C. Wainwright 23rd Annual Global Investment Conference

BRIDGEWATER, N.J., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica” or the “Company”), a fully integrated biopharmaceutical company, announced today that Brian Markison, Chief Executive Officer, and James “JD” Schaub, Chief Operating Officer, will present

August 30, 2021

Osmotica Pharmaceuticals plc Closes Sale of Legacy Business to Alora Pharmaceuticals, LLC

-- Divestiture advances Company's transformation and emphasis on eye care and ocular aesthetics -- -- Proceeds of the sale will be used to retire a substantial portion of outstanding debt -- BRIDGEWATER, N.J., Aug. 30, 2021 (GLOBE NEWSWIRE) -- Osmotica Pharmaceuticals plc (Nasdaq: OSMT) (“Osmotica”

August 16, 2021

Osmotica Pharmaceuticals plc Reports Second Quarter 2021 Results and Provides Business Update

Sale of legacy business to Alora Pharmaceuticals, LLC expected to close in third quarter 2021 Second quarter 2021 total Upneeq revenue of $11.5 million including a $10.0 million milestone payment from Santen Pharmaceutical Co., Ltd Upneeq prescriptions nearly doubled in the second quarter compared

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Displaying 1 - 10 of 28

Investor Relations

News

Press Releases

Press Releases

Press Releases